Format

Send to

Choose Destination
Indian J Med Microbiol. 2018 Oct-Dec;36(4):513-516. doi: 10.4103/ijmm.IJMM_18_172.

Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China.

Author information

1
Center for Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
2
Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.

Abstract

Backgrounds:

This randomised controlled, open-label, non-inferiority trial was conducted in antiretroviral-naïve HIV-1-infected patients to assess the efficacy and safety of 48-week dual therapy of LPV/r plus 3TC (DT group) compared with Chinese first-line triple-therapy regimen (TT group).

Methods:

198 were randomised to DT (n = 100) or TT (n = 98).

Results:

Ninety-two DT patients (92%) and 88 TT patients (89.8%) achieved HIV-1 RNA <50 copies/ml at week 48 (P = 0.629). Moreover, the safety profile was similar between two groups, and no secondary HIV resistance was observed.

Conclusion:

The results suggest that dual therapy of LPV/r plus 3TC is non-inferior to the first-line triple-therapy regimen in China.

KEYWORDS:

Antiretroviral therapy; efavirenz; lopinavir/ritonavir; randomised controlled study; simplified regimen

PMID:
30880698
DOI:
10.4103/ijmm.IJMM_18_172

Supplemental Content

Loading ...
Support Center